(NYSE: NVO) Novo Nordisk A S's forecast annual revenue growth rate of 19.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.35%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Novo Nordisk A S's revenue in 2024 is $35,142,877,697.On average, 2 Wall Street analysts forecast NVO's revenue for 2024 to be $191,332,979,640,000, with the lowest NVO revenue forecast at $186,936,658,700,000, and the highest NVO revenue forecast at $195,729,300,580,000. On average, 3 Wall Street analysts forecast NVO's revenue for 2025 to be $236,100,953,440,000, with the lowest NVO revenue forecast at $232,943,529,500,000, and the highest NVO revenue forecast at $238,749,541,140,000.
In 2026, NVO is forecast to generate $270,059,142,760,000 in revenue, with the lowest revenue forecast at $261,696,989,400,000 and the highest revenue forecast at $278,421,300,630,000.